You are here

NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA)

Description:

NIAAA supports research on the causes, prevention, control, and treatment of the major health problems associated with alcohol use. Through its extramural research programs, NIAAA funds a wide range of basic and applied research to develop new and/or improved technologies and approaches for increasing the effectiveness of diagnosis, treatment, and prevention. NIAAA also is concerned with strengthening research dissemination, scientific communications, public education, and data collection activities in the areas of its research programs. For additional information about areas of interest to the NIAAA, you are invited to visit our home page at http://www.niaaa.nih.gov. Phase IIB Competing Renewal Awards NIAAA will accept SBIR/STTR Phase IIB Competing Renewal grant applications from Phase II SBIR/STTR awardees to continue the process of developing products that require approval of a Federal regulatory agency (e.g., FDA, FCC). Such products include, but are not limited to, medical implants, drugs, vaccines, and new treatment or diagnostic tools that require FDA approval. This renewal grant should allow small businesses to get to a stage where interest and investment by third parties is more likely. Please contact Dr. Max Guo (contact information provided below) before beginning the process of putting an application together. Prospective applicants are strongly encouraged to contact NIH staff prior to submission of a Competing Renewal application. Prospective applicants are strongly encouraged to submit to the program contact a letter of intent that includes the following information: • Descriptive title of the proposed research • Name, address, and telephone number of the Principal Investigator • Names of other key personnel • Participating institutions • Funding Opportunity Announcement Number (e.g., PA-10-XXX) Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NIH staff to estimate the potential review workload and plan the review. It is expected that only a portion of NIAAA SBIR/STTR Phase II awards will be eligible for a Phase IIB Competing Renewal grant. The following examples would make appropriate topics for proposed SBIR or STTR Phase IIB Competing Renewal projects. These examples are meant for illustrative purposes and are not exclusive of other appropriate activities: • Preclinical studies, including pharmacology and toxicology, beyond those conducted under the Phase I (R43) and initial Phase II (R44) grants. Some in vivo or in vitro studies would be expected to have been carried out in Phase I or the initial Phase II grant. • Completion of studies as required by the Food and Drug Administration (FDA) for Investigational New Drug (IND) or Radioactive Drug Research Committee (RDRC) application • Development and clinical evaluation of new alcohol-sensitive biomarkers • Assessment of devices with regard to performance standards related to the FDA approval process • Safety and effectiveness studies of novel medical devices • Biocompatibility studies of surface materials of putative medical implants • Evaluation of novel imaging approaches for diagnostic purposes • Clinical studies in support of New Drug Application approval by the FDA • Clinical studies in support of Pre-Market Approval for biomarkers/medical devices by the FDA Direct your questions about scientific/research issues to: Q. Max Guo, Ph.D. Phone: 301-443-0639 Email: Max.Guo@nih.gov Pharmaceutical Development for Alcoholism Treatment The topic focuses on applied and, where appropriate, clinical research on pharmacologic agents for use in the treatment or medical management of alcoholism, disorders resulting from alcoholism, the improvement and refinement of drugs currently available for therapeutic purposes, or drugs suitable for use in basic research studies on alcohol addiction. Areas that may be of interest to small businesses include, but are not limited to: A. Development of agents to attenuate drinking behavior, e.g., drugs to curb craving B. Development of aversive agents such as disulfiram that can attenuate drinking behavior C. Development of agents to treat acute alcohol withdrawal D. Development of drugs that are capable of improving or reversing alcohol-induced cognitive impairments E. Development of agents to induce sobriety in intoxicated individuals (i.e., amethystic agents) F. Development of agents to treat associated psychiatric disorders and/or drug abuse, and to diminish drinking G. Development of improved methods of drug delivery for the treatment of alcoholism. The systems developed must be capable of maintaining therapeutic drug levels for extended periods of time to alleviate compliance problems. H. Development of drugs for the treatment of alcoholic hepatitis, cirrhosis, pancreatitis, cardiomyopathy, or other alcohol-induced tissue damage I. Research on the pharmacodynamics and pharmacokinetics of concurrent ethanol and other drug use. For clinical questions, contact: Joanne B. Fertig, Ph.D. 301-443-0635 Email: Joanne.Fertig@nih.gov For pre-clinical questions, contact: Mark Egli, Ph.D. (Neuroscience and behavior) 301-594-6382 Email: Mark.Egli@nih.gov Svetlana Radaeva, Ph.D. (Organ damage) 301-433-1189 Email: sr252a@nih.gov Diagnostic Assessment of Alcohol Use Disorders and Comorbidity Innovative self-report and biochemical approaches to the early identification of alcohol use problems and diagnosis of alcohol use disorders and comorbidity are needed. The research design should include measurements of reliability and validity in appropriate population samples. Areas that may be of interest to small businesses include, but are not limited to: A. Development or adaptation of diagnostic instruments measuring alcohol use disorders and related comorbid conditions in general population and treated samples, including youth, the elderly, pregnant women, ethnic minorities, the handicapped, and persons with low-level reading skills). B. Development and testing of computer algorithms necessary to derive diagnoses of alcohol use disorders and associated comorbidity. C. Development of innovative methods for diagnostic assessment in clinical settings. Development and testing of detailed audio, visual, or printed training modules to accompany diagnostic instruments. Cherry Lowman, Ph.D. 301-443-0637 Email: Cherry.Lowman@nih.gov Treatment of Alcoholism A. Development and evaluation of innovative therapeutic approaches across the continuum of alcoholism care. B. Development and validation of tools to aid in the clinical management of patients, including selection of appropriate interventions, process evaluation, assessment of outcome, aftercare, and patient tracking, in various treatment settings. Cherry Lowman, Ph.D. 301-443-0637 Email: Cherry.Lowman@nih.gov Alcohol Biosensors and Data Analysis Systems It is anticipated that innovative and improved alcohol sensors would be useful in a variety of situations including, but not limited to, clinical monitoring, forensics and human or animal research. Specific sensor characteristics would complement their intended use. This applies to characteristics such as sampling frequency, degree of accuracy, data storage capacity and data transmission frequency. Depending on their intended purpose and use, alcohol sensors may be augmented with additional information such as other physiological measurements or geospatial determinations. Devices need to be compatible with human comfort, and devices to be worn for weeks or months may present particular challenges. Since alcohol readings are likely to be baseline most of the time, these sensing devices generally require ways to monitor contact and readiness to record. Moreover, where necessary, measurement fidelity should be robust to subject's activities including active efforts at tampering. The mode of data storage will need to conform to power limitations and strategies for data transmission which may require telemetry. In addition to alcohol monitoring and data transmission this program also includes the opportunity to develop appropriate data analysis systems. Examples include: estimating blood alcohol concentrations, reconstructing patterns of alcohol consumption, and monitoring large numbers of devices to identify significant, but infrequent, events while minimizing false positives. R. Thomas Gentry, Ph.D. 301-443-6009 Email: Tom.Gentry@nih.gov Promoting Adherence to Medical, Pharmacologic, and Behavioral Treatments for Alcohol Use Disorders Several recent reports and literature reviews point to the continuing need for improving adherence to therapeutic regimens. Adherence rates vary considerably across diseases and treatments, measuring instruments, and populations, with rates ranging from 30% to 60% in many instances. The reasons for non-adherence are multifaceted. Health-care providers, organizational systems, and patient factors all play a role in adherence to therapeutic regimens. Thus, to understand and eventually improve adherence, conceptual frameworks and interventions need to take into account institutional, system, situational, interpersonal, and personal factors as well as the characteristics of the illness or condition and of the treatment regimen. While extensive research exists and successful techniques have been identified, greater efforts are needed to develop and implement programs based upon these findings. Applications are sought to develop: A. Programs to implement effective interventions and to evaluate their implementation. B. Professional education courses or web-based training modules on interventions and to monitor their effectiveness. In both cases, the emphasis is on how to encourage health practitioners to utilize interventions that will improve their patients’ adherence to medical, pharmacologic, and behavioral regimens for alcohol abuse and dependence. Margaret E. Mattson, Ph.D. 301-443-0638 Email: Margaret.Mattson@nih.gov Prevention This area of interest focuses on the development and evaluation of innovative prevention and intervention programs, or specific materials for integration into existing programs, which utilize state-of-the-art technology and are based on currently accepted clinical and behavioral strategies. Applicants are strongly encouraged to consult with research methodologists and statisticians to ensure that state-of-the-art approaches to design, analysis, and interpretation of studies under this topic are used. Areas that may be of interest to small businesses include, but are not limited to: A. Development and evaluation of innovative prevention/intervention programs, or specific materials for integration into existing programs, which utilize state-of-the-art technology and are based on currently accepted clinical and behavioral strategies. Special emphasis should be placed on the needs of high-risk groups, ethnic and minority populations, youth, children of alcoholics, women, the handicapped, and the elderly. Examples of such materials include school-based curricula, interactive videos, computer-based multimedia programs, training manuals for teachers or parents, and community-based programs. B. Development and evaluation of educational materials designed to intervene with the elderly around specific age-related risks for alcohol problems. Particular attention should be given to age-related reductions in alcohol tolerance, interactions between alcohol and prescription and over-the-counter medications, possible exacerbation of some medical conditions common among the elderly, potential biomedical and behavioral consequences of excessive alcohol use, and the role of alcohol in falls, fires, burns, pedestrian and traffic injuries, and other unintentional injuries. C. Development and evaluation of statistical analysis programs tailored to the design and analysis of alcohol prevention-relevant research. Programs could focus on a variety of areas including: imputation of missing data under varying design assumptions; simulation of distributions of outcomes based on varying mixtures of sample populations; application of chronic or infectious disease models to targeted communities; and models of the potential effect of various policy-based interventions, such as increased taxation or reduction of outlet density by license revocation and control. Robert C. Freeman, Ph.D. 301-443-8820 Email: Robert.Freeman@nih.gov Health Services Research on Alcohol-Related Problems Research projects are sought that will expand knowledge and improve delivery of alcohol treatment and prevention services. The research objectives include, but are not limited to, the effects of organizational structures and financing mechanisms on the availability, accessibility, utilization, delivery, content, quality, outcomes, and costs of alcohol treatment services. Objectives also include studying the effectiveness and cost-effectiveness of alcohol prevention services in reducing the demand for health care services and improving the methodological tools useful for conducting health services research. Areas that may be of interest to small businesses include, but are not limited to: A. Development and assessment of protocols to assist in the identification, recruitment, and selection of treatment personnel to enhance the matching of staff to program needs. B. Development and assessment of computer software or other protocols to assist in the management of treatment delivery. Software should be useful for assessment, diagnosis, patient placement criteria, monitoring of services received, tracking patient progress, and billing. C. Development and assessment of software to assist clinicians in scoring and assessment of score norms for commonly used assessment instruments. These packages should include protocols for guiding client feedback in a clinic or office-based setting. D. Development and assessment of software or other protocols to assist treatment programs and service agencies in measuring, assessing, or otherwise documenting clinically relevant performance indicators or improvements in quality of service provision. E. Development and assessment of protocols to facilitate the selection, implementation, adoption, and maintenance of evidence-based services consistent with target population need, staffing and program resources, and expected outcomes. These protocols should be flexible enough to work across a variety of settings and modalities. F. Development and assessment of software or other protocols to facilitate the incorporation of screening and identification tools into routine usage in primary care, emergency, obstetric, mental health, and other health care settings. Research projects should facilitate both the provisions of brief interventions, medical management, effective referral to specialized alcohol treatment, and follow-up. G. Development and assessment of software or other protocols for monitoring service costs of alcohol treatment services including core, ancillary, out-sourced services. These tools should provide a user-friendly system of monitoring costs that could be implemented without additional accounting expertise by the staff at a typical treatment setting. At the same time, such tools should be defensible as measures of the true opportunity costs of providing alcohol treatment services. Such software might be bundled with billing software. Robert Huebner, Ph.D. 301-443-4344 Email: Bob.Huebner@nih.gov Fetal Alcohol Spectrum Disorder (FASD) and Alcohol-Related Birth Defects FASD is the collective term for the broad array of documented adverse effects resulting from in utero alcohol exposure. The most serious of these is fetal alcohol syndrome (FAS), a devastating developmental disorder characterized by craniofacial abnormalities, growth retardation, and nervous system impairments that may include mental retardation. Other diagnostic categories include partial FAS, alcohol-related neurodevelopmental disorder (ARND), and alcohol-related birth defects (ARBD). Children and adults with FASD may exhibit multiple cognitive, behavioral, and emotional deficits that impair daily functioning in many domains. The NIAAA supports research leading to improved diagnosis and assessment of impairment and disability, as well as the development of tools to enhance academic and daily living skills. Areas that may be of interest to small businesses include, but are not limited to: A. Development and assessment of diagnostic and/or screening methods that can be used prenatally to identify fetuses affected by ethanol. B. Development and validation of biomarkers that can be used to verify prenatal alcohol exposure in neonates. C. Development and validation of assessment methods to provide more accurate clinical diagnosis of FASD at all life stages. D. Development and testing of skill-building, therapeutic, and education program products that enhance the social, cognitive, adaptive and motor abilities of individuals with FASD. E. Development of neurobehavioral tools or instruments to assess responsiveness of individuals with FASD to medications and/or cognitive/behavioral therapies. F. Development of accurate measures of the responsiveness of children affected by prenatal exposure to alcohol to stress and predictors of vulnerability to alcohol-drinking or other psychopathology during adolescence and adulthood. G. Development and evaluation of educational and training programs designed to enhance the skills of non-professional caregivers in dealing with the problems associated with FAS. H. Development and validation of innovative approaches to prevent harmful drinking during pregnancy. For basic research questions, contact: Dale Hereld, MD, Ph.D. 301-443-0912 Email: Dale.Hereld@nih.gov William C. Dunty, Ph.D. 301-443-7351 Email: William.Dunty@nih.gov For prevention research questions, contact: Marcia Scott, Ph.D. 301-402-6328 Email: Marcia.Scott@nih.gov Alcohol Use and HIV, HBV, or HCV Infection Alcohol use, including hazardous drinking, by persons infected with HIV, HBV, and HCV, is quite common in the United States. Alcohol consumption is widely acknowledged as a co-factor in the sexual transmission, susceptibility to infection, and progression of the infectious diseases. However, detailed relationships between alcohol use and viral infections, diseases progression, antiretroviral therapy and adverse outcomes, notably in liver disease progression, are less recognized or understood. Recent research indicates that inflammatory pathways predominate in alcoholic hepatitis whereas adaptive immunity plays a primary role in viral hepatitis, offering multiple targets for novel preventive and therapeutic interventions. Comprehensive studies to improve understanding of the factors underlying alcohol and viral etiologies in liver disease and the impact of antiretroviral drugs on liver disease progression are needed. A better understanding of alcohol’s effects on liver disease in patients with HIV/HBV/HCV infection may improve diagnosis and treatment outcomes. NIAAA supports research leading to improved diagnosis and treatment of alcohol-induced disorders in people infected with HIV, HBV, or HCV. Areas that may be of interest to small businesses include, but are not limited to: A. New preventive and therapeutic approaches designed to protect the liver from alcohol and antiretroviral drug-induced liver injury in patients infected with HIV, HBV, or HCV. B. Development of therapies aimed at molecular targets that play a role in the development of alcoholic and viral liver diseases. C. Develop and evaluate drugs that mitigate the effects of oxidative stress on mitochondrial function thereby preventing liver disease progression. D. Development of biomarkers for individuals who are most prone to alcohol-induced damage in those patients infected with HIV, HBV, or HCV. For HBV/HCV and basic research questions on HIV, contact: H. Joe Wang, Ph.D. 301-451-0747 Email: He.Wang@nih.gov For clinical or epidemiological questions on HIV, contact: Kendall J. Bryant, Ph.D. 301-402-9389 Email: Kendall.Bryant@nih.gov Research Tools The NIAAA supports the development of new or improved tools to enhance the ability to conduct alcohol-related laboratory studies on humans and animals and to more effectively analyze data from large databases. Examples include transgenic animal models, cell lines, new ligands for neuroimaging, and simulators of alcohol impairment. Areas that may be of interest to small businesses include, but are not limited to: A. Development of novel animal models, including transgenic animals, possessing specific traits of significance for the study of alcoholism, or for the study of specific pathologic disease states which arise from excessive alcohol consumption. B. Development of a hepatocyte cell line capable of maintaining viability and metabolic functions in culture systems for an indefinite period. C. Development of new methods of ethanol administration to animals that produce precise dose control or that closely mimic types of alcohol exposure occurring in humans, including, but not limited to, binge drinking, acute consumption, moderate consumption and chronic consumption. D. Development of specialized cell culture chambers to provide controlled administration of ethanol to in vitro cell systems. E. Development of ligands which will enhance the potential usefulness of PET and SPECT imaging technologies for the study of the etiology of alcoholism and related brain pathology. F. Development of genetic, epigenetic, genomic, proteomic, metabolomic, lipidomic, glycomic or other systems-wide methods for assessment, prognosis, diagnosis or treatment of alcohol-induced disorders. G. Development of computational, statistical or bioinformatics tools to organize and manage high throughput data obtained by genomic, functional genomic or other ‘omic strategies. H. Development of databases, methods for integration of databases, or data analysis systems for alcohol research. Kathy Jung, Ph.D. 301-443-8744 Email: Mary.Jung@nih.gov Development of Biomolecular Signatures of Alcohol Exposure and Alcohol-induced Tissue Injury Acute and chronic alcohol consumption leads to health-related complications and ultimately to significant societal costs. Quantitative and qualitative markers of high-risk drinking behavior and alcohol-induced tissue damage would greatly improve medical efforts to recognize and treat alcohol-related disorders. Traditional biomarkers currently in clinical use lack specificity, sensitivity, and accuracy, and fail to provide long-term information. Biomarkers of sufficient reliability, sensitivity and specificity are likely to be comprised of a panel of physiological parameters, rather than a single molecular entity. Thus, NIAAA seeks to support the discovery and development of pattern-based molecular fingerprints or signatures of alcohol consumption and of alcohol-induced tissue injury. High throughput approaches using genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipomics, or glycomics are encouraged. Biomarker signatures may be composed of multiple genes, RNAs, microRNAs, proteins, or metabolites, or combinations thereof. Furthermore, alterations in lipid, lipoprotein, or glycoprotein profiles may reflect the metabolic effects of alcohol exposure and may be considered as potentially predictive. Biomarker signatures that address multiple aspects of alcohol consumption and alcohol damage are needed. These include, but are not limited to: A. Biomarkers of long-term alcohol consumption. A biomarker panel reflecting the cumulative intake of alcohol over a period of months or more would be of great diagnostic use, both in terms of recognizing problem drinking and in terms of the potential for organ damage. B. Biomarkers that distinguish between binge, acute, moderate and chronic drinking. Each of these modes of alcohol intake has different physiological effects. The ability to distinguish dose and timing of drinking would enhance clinicians’ ability to design appropriate treatment and intervention protocols. C. Biomarkers of compliance after withdrawal. Biomarker signatures in this class would be comprised of metabolic products that decrease rapidly upon abstinence, in contrast to the characteristics of biomarkers that reflect cumulative alcohol. The ability to detect relapse accurately will support successful behavioral interventions. D. Biomarker signatures of alcohol-induced organ damage. The damage due to alcohol consumption is likely to be organ-specific, with signatures reflecting alcohol-induced damage likely to be different for heart damage, liver damage, encephalopathy, a dysregulated immune system, or other alcohol target. E. Biomarker signatures of familial risk factors for alcoholism. Early identification of subjects predisposed to alcoholism will allow for early intervention, and allow the subject to make informed decisions. Kathy Jung, Ph.D. 301-443-8744 Email: Mary.Jung@nih.gov Clinical Testing of Biochemical Markers The development of effective biochemical markers represents a powerful means for early diagnosis and treatment of alcohol dependent/abuse patients and for the identification of individuals who have a predisposition for alcoholism. There are two different types of biochemical markers: trait markers and state markers. Trait biomarkers have the ability to detect inborn characteristics of individuals who are vulnerable for alcoholism. This type of marker would be invaluable for screening of high-risk individuals (e.g., children of alcoholics) and targeting them with preventive or early treatment interventions. In addition, trait markers might assist practitioners in identifying subpopulations of alcoholics who may need different treatment strategies. An ideal trait marker should have several features. First, it should display validity in detecting people susceptible to alcoholism, particularly before the onset of alcoholism or during periods of stable abstinence. Second, it should be easily and reliably measured. Third, it should be specific for alcoholism only and not affected by other medical or psychiatric disorders or drugs. Since alcoholism is a complex disease, it is likely that more than one type of gene and protein exist as trait marker. State markers or markers of alcohol consumption serve several important purposes. First, they can assist physicians in diagnosing individuals with chronic drinking problems, particularly patients who deny excessive drinking. Moreover, they may also identify individuals in early stages of heavy drinking, thus avoiding the long-term medical, psychological, and social consequences of chronic alcoholism. Second, state biomarkers can aid in the diagnosis and treatment of other diseases (liver diseases, pancreatitis, and cardiovascular diseases) that were, at least, caused by excessive drinking. Third, they are useful in alcohol treatment and prevention programs. Since the goal of many of programs is abstinence, monitoring relapse is important in gauging success. Last, state biomarkers are important in clinical alcohol trials. Although self-reports have become more sophisticated and valid (e.g., Timeline Followback), they still rely on accurate reporting. These new and reliable biomarkers could then be used to confirm the self-report. Several biomarkers with certain limitations are currently in use including carbohydrate-deficient transferrin (CDT), gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and mean corpuscular volume (MCV). New state markers need to be developed that incorporate the following attributes: validity, reliability, stability, cost, practicability, acceptability, and transportability. Areas that may be of interest to small businesses include, but are not limited to: A. Develop and evaluate clinically alcohol-sensitive biomarkers to identify individuals who are predisposed to alcoholism; determine relapse; measure levels of drinking; and determine alcohol-induced tissue damage. B. Identify genes, and proteins that are expressed during the development of alcohol dependence for biomarker development. C. Develop methodologies for high throughput identification of alcohol metabolites and other signaling molecules that are expressed during alcohol intake. D. Use knowledge of genetic and molecular mechanisms underlying alcohol-induced organ damage (including alcohol-related liver, pancreas, heart disease and FAS) to develop new biomarkers of tissue and cell damage. E. Evaluate clinically innovative alcohol-sensitive biomarkers (trait, relapse, organ damage) for sensitivity and specificity. Raye Z. Litten, Ph.D. 301-443-0636 Email: Raye.Litten@nih.gov Stem Cell Research for Alcohol-induced Disorders Stem cells are master cells in the body and they have the remarkable potential to develop into many different cell types. Stem cells may become a renewable source of replacement cells to treat alcohol related diseases. They can also be used to study disease processes, and to develop new and more effective drugs. Recent research progress on stem cells has offered great opportunities to study conditions and diseases related to alcohol abuse and alcoholism. Stem cells can come from embryos or adult tissues. They are generally categorized into 1) Embryonic stem cells; 2) Induced pluripotent stem cells (iPS cells); and 3) Adult stem cells. The NIAAA supports SBIR/STTR research using any of these 3 types of stem cell, which can lead to improved understanding of alcohol related diseases and conditions, and better treatment. Areas that may be of interest to small businesses include, but are not limited to: A. Generate and disseminate induced pluripotent stem cells (iPS) from mature human cells to resemble diverse individual variations regarding alcohol metabolism. Use these genetic variant models to study alcohol dependence and pharmacotherapy development. Examples of these genetic variations include Alcohol Dehydrogenase (ADH), Aldehyde Dehydrogenase (ALDH), cytochrome P450 isozyme CYP2E1, and Glutathione S transferase (GST). B. Generate and disseminate disease-specific iPS cell lines for studies on the biology and signaling pathways that contribute to the alcohol-related disease pathology. C. Study the potential of using patient-specific iPS cells for cell replacement therapies to treat alcohol-caused tissue damages. Peter Gao, M.D. 301-443-6106 Email: Peter.Gao@nih.gov Real-time Detection of Neurochemical Changes in Response to Alcohol Drinking Many pharmacological mechanisms of ethanol action in the brain are mediated by time-dependent neurochemical events in multiple brain regions. Despite great progress in identifying ethanol’s neurochemical actions, we do not fully know how neurochemicals change in real time following ethanol administration and drinking (acute and chronic). Multidimensional measurement of neurochemical change (i.e., concentration, time, region) are needed to reveal kinetics underlying alcohol effects to guide future medication development and promote mechanistic understanding of alcohol drinking. With this SBIR/STTR grant solicitation, NIAAA seeks development of biosensors enabling monitoring of regional neurochemical changes in the brains of rats and/or mice in real time as they drink alcohol. Recent studies report the plausibility of using microsensors coupled with wireless detection methods to instantaneously monitor multiple neurochemical changes in animals. NIAAA seeks development of microsensors with sufficient resolution to provide neuroanatomical regional specificity. In addition to brain ethanol concentration, neurochemicals of interest include, but are not limited to, glutamate, dopamine, GABA, acetylcholine, and signaling molecules. Work under this solicitation should be directed toward the development of commercial strategies for the real-time measurement of extracellular neurochemical and brain ethanol concentrations in behaving animals. Changhai Cui, Ph.D. 301-443-1678 Email: Changhai.Cui@nih.gov Mark Egli, Ph.D. 301-594-6382 Email: Mark.Egli@nih.gov Other Research Topic(s) Within the Mission of the Institute For additional information on research topics, contact: Q. Max Guo, Ph.D. National Institute on Alcohol Abuse and Alcoholism 5635 Fishers Lane, Room 2037 Bethesda, MD 20892-9304 For Federal Express delivery, use: Rockville, MD 20852-1705 Phone: 301-443-0639 Email: Max.Guo@nih.gov For administrative and business management questions, contact: Ms. Judy Fox Grants Management Officer National Institute on Alcohol Abuse and Alcoholism Phone: 301-443-4704, Fax: 301-443-3891 Email: Judy.Fox@nih.gov
US Flag An Official Website of the United States Government